Stifel Nicolaus Forecasts Strong Price Appreciation for Enliven Therapeutics (NASDAQ:ELVN) Stock

Enliven Therapeutics (NASDAQ:ELVN) had its price target increased by investment analysts at Stifel Nicolaus from $80.00 to $82.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ price objective points to a potential upside of 35.63% from the stock’s previous close.

ELVN has been the topic of a number of other reports. Guggenheim dropped their target price on shares of Enliven Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a report on Thursday. HC Wainwright lifted their price target on Enliven Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a report on Thursday, July 9th. Mizuho boosted their price target on Enliven Therapeutics from $45.00 to $62.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Friday, July 17th. Finally, JonesTrading raised their price objective on Enliven Therapeutics from $45.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Enliven Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $72.67.

Enliven Therapeutics Trading Up 0.3%

NASDAQ:ELVN opened at $60.46 on Thursday. The stock has a market capitalization of $3.68 billion, a PE ratio of -36.20 and a beta of 0.27. Enliven Therapeutics has a 1-year low of $14.78 and a 1-year high of $62.32. The firm has a fifty day simple moving average of $48.62 and a 200 day simple moving average of $39.68.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10). On average, equities analysts predict that Enliven Therapeutics will post -1.57 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Benjamin Hohl sold 6,018 shares of the company’s stock in a transaction dated Friday, July 17th. The shares were sold at an average price of $52.64, for a total value of $316,787.52. Following the transaction, the chief financial officer owned 46,054 shares in the company, valued at approximately $2,424,282.56. This represents a 11.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Anne Kunkel sold 10,000 shares of the stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $50.49, for a total transaction of $504,900.00. Following the completion of the transaction, the director directly owned 41,884 shares in the company, valued at approximately $2,114,723.16. This represents a 19.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 190,831 shares of company stock valued at $10,991,723. Company insiders own 3.00% of the company’s stock.

Institutional Trading of Enliven Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. KBC Group NV acquired a new position in Enliven Therapeutics in the 1st quarter valued at $38,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Enliven Therapeutics by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after acquiring an additional 594 shares in the last quarter. BNP Paribas Financial Markets grew its stake in shares of Enliven Therapeutics by 33.3% in the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after acquiring an additional 930 shares in the last quarter. Los Angeles Capital Management LLC bought a new position in Enliven Therapeutics during the fourth quarter worth about $83,000. Finally, Quantbot Technologies LP increased its position in Enliven Therapeutics by 47.1% during the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after acquiring an additional 1,434 shares during the period. 95.08% of the stock is owned by institutional investors and hedge funds.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.